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ABSTRACT 
 
It is well known that early-life experiences modulate brain development and affect the 
behavior in later life. However, the brain mechanisms underlying effects of environmental 
factors on the development of behaviors are less known. In the present study, I investigated 
the roles of 5-HT and the 5-HT1A receptor during the postnatal period in the behaviors in 
adulthood. I orally administered the selective 5-HT reuptake inhibitor (SSRI) (fluoxetine) or 
5-HT1A receptor agonist (8-OH-DPAT) from postnatal day (P) 1 to P21. Treatment with 
fluoxetine and 8-OH-DPAT during the postnatal period decreased anxiety-like behavior in 
adulthood, suggesting that 5-HT has anxiolytic effect, which is at least mediated through 
5-HT1A receptor. In contrast, 8-OH-DPAT treatment during the postnatal period increased 
depression-like behavior in the forced swim test, but not in the sucrose preference test, 
whereas fluoxetine treatment had no effects in depression-like behavior. This suggests that 
the postnatal 5-HT1A receptor has opposite effects on anxiety and depression in adulthood. 
Treatment with fluoxetine and 8-OH-DPAT during the postnatal period had no significant 
effects on the spatial learning and memory and pain sensitivity. Next, as an approach to 
elucidate the brain mechanisms underlying the effects of fluoxetine and 8-OH-DPAT on the 
anxiety and depression-like behaviors in adulthood, I measured the gene expressions that 
have been shown to be involved in anxiety and depression-like behaviors. Treatment with 
both fluoxetine and 8-OH-DPAT decreased the mRNA expressions of the GABAA receptor 
α3 subunit in the medial prefrontal cortex (mPFC) and ventral hippocampus at P71. On the 
basis of the correlative changes between behavior and the mRNA expression, it is possible 
that the GABAA receptor α3 subunit in the mPFC and ventral hippocampus may modulate 
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anxiety-like behavior. In contrast, 8-OH-DPAT treatment decreased the mRNA expressions 
of the 5-HT1A receptor, brain-derived neurotrophic factor (BDNF) and the GABAA receptor 
α2 subunit in the mPFC and the GABAA receptor α2 subunit in the ventral hippocampus at 
P71, whereas fluoxetine had no effects on these gene expressions. On the basis of the 
correlative changes between behavior and the mRNA expression, it is suggested that the 
5-HT1A receptor, BDNF, and the GABAA receptor α2 subunit in the mPFC and the GABAA 
receptor α2 subunit in the ventral hippocampus may modulate depression-like behavior. In 
summary, activation of the 5-HT1A receptor during the postnatal period may reduce anxiety 
levels, but increase depression levels during adulthood via different multiple molecules in the 
mPFC and ventral hippocampus. 
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INTRODUCTION 
 
Effects of early-life experiences on the development of brain and behaviors 
Early-life experiences are known to alter brain development and behaviors in later life. The 
quality of maternal care and mother-infant relationship is associated with various 
developmental outcomes, such as emotionality and cognition. In humans, a secure attachment 
with mothers, in which mothers respond to infant’s signals accurately and consistently, 
provides the infants with better emotional regulation and better handling stressful situation 
(Baram et al., 2012). In contrast, poor maternal care or mother-infant relationship makes the 
infants vulnerable to stressful situations and at high risk of developing depression (Lupien et 
al., 2009; Baram et al., 2012). To study the roles of maternal care and mother-infant 
relationship in the development of infant, maternal separation is used as animal models. 
Prolonged maternal separation for 1-6 hours a day increases both anxiety and depression-like 
behaviors in the adulthood, and impairs the brain development including hyperactivity of 
hypothalamic-pituitary-adrenal (HPA) axis and low level of neurotrophins (Nishi et al., 2014; 
Tractenberg et al., 2016). In contrast, brief maternal separation for 3-15 minutes a day during 
the postnatal period decreases anxiety-like behavior and improve spatial learning and 
memory in the adulthood, which is accompanied by lower HPA axis responsiveness 
(Vetulani et al., 2013; Nishi et al., 2014; Raineki et al., 2014). These positive effects may be 
due to increased maternal care, induced by brief maternal separation (Vetulani et al., 2013). 
Thus, human and animal studies have reported the crucial roles of early-life experiences in 
the development of the brain and behaviors. However, the brain mechanisms (molecules and 
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brain regions), which link early-life experiences to behavioral changes in later lifer, are not 
well known. 
 
Serotonin in the development 
Serotonin (5-hydroxytryptamine, 5-HT) is known as a neurotransmitter in the adult brain. In 
addition, 5-HT neurons appear early in the embryonic brain and 5-HT has neurotrophic 
activity. In mice, 5-HT neurons emerge at embryonic day (E) 10 to E12 in the raphe nuclei, 
and extend the axons to widespread brain regions like the prefrontal cortex, hippocampus, 
and amygdala between E14.5 and postnatal day (P) 0 (Gaspar et al., 2003; Kepser and 
Homberg, 2015). Both in vivo and in vitro studies have revealed various roles of 5-HT in the 
neural development. For example, in vivo studies show that selective 5-HT reuptake inhibitor 
(SSRI) fluoxetine treatment during the postnatal period decreases the complexity of dendritic 
arbors in the prefrontal cortex (Ko et al., 2014; Rebello et al., 2014), whereas increases the 
number and the length of dendritic spines in the hippocampus in adolescence and adult 
(Zheng et al., 2011; Guidi et al., 2013). Besides dendrite formation and synaptogenesis, 
postnatal 5-HT also affects adult behaviors. For example, fluoxetine treatment during the 
postnatal period increases adult anxiety level (Ansorge et al., 2004; Rebello et al., 2014; 
Sarkar et al., 2014) and depression level (Karpova et al., 2009; Ko et al., 2014; Rebello et al., 
2014; Sarkar et al., 2014). In contrast, postnatal fluoxetine treatment recovers impaired 
spatial learning as well as 5-HT turnover and synapse formation in prenatally stressed mice 
(Ishiwata et al., 2005). Thus, 5-HT during the postnatal period may be one of important 
factors to modulate adult behaviors.  
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The 5-HT1A receptor in the development 
Until today, at least 14 5-HT receptors with 7 classes were reported. Among these 5-HT 
receptors, the 5-HT1A receptor has been extensively studied. In the development, the 5-HT1A 
receptor begins to appear at E12 in rat (Hillion et al., 1993) and by E14.5 in mouse brains 
(Bonnin et al., 2006). Subsequently, the expression level of the 5-HT1A receptor reaches to 
the peak during the prenatal and postnatal periods, depending on the brain regions (Daval et 
al., 1987; Hillion et al., 1993; Bonnin et al., 2006). The 5-HT1A receptor is localized both 
presynaptically and postsynaptically. Both presynaptic and postsynaptic 5-HT1A receptors are 
coupled to Gαi/o proteins to increase intracellular calcium concentration through adenylate 
cyclase and protein kinase A (Polter and Li, 2010). Presynaptic 5-HT1A receptor 
(autoreceptor) is expressed in 5-HT neurons in the raphe nucleus, leading to a decrease in the 
firing of 5-HT neurons and 5-HT release. On the other hand, postsynaptic 5-HT1A receptor 
(heteroreceptor) is localized on non-5-HT neurons, such as glutamatergic, GABAergic and 
cholinergic neurons, in the cortex, amygdala, and hippocampus. Activation of the 5-HT1A 
heteroreceptor usually decreases neuronal excitability and firing. 
  Similar to the 5-HT actions, the 5-HT1A receptor modulates dendrite formation and 
synaptogenesis. The 5-HT1A receptor inhibits dendritic spine formation in the cortex 
(Yoshida et al., 2011) whereas it promotes dendritic spine formation and synaptogenesis in 
the hippocampus (Yan et al., 1997; Wilson et al., 1998; Mogha et al., 2012).  
  In addition, many studies have reported the relationships between postnatal 5-HT1A 
receptor and adult behaviors. Postnatal 5-HT1A receptor is particularly correlated with 
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anxiety-like behavior. By use of conditional knockout of the 5-HT1A receptor and treatment 
with a 5-HT1A receptor antagonist, it has been shown that blockade of the 5-HT1A receptor 
during the postnatal period increases anxiety-like behavior in adulthood (Gross et al., 2002; 
Vinkers et al., 2010). In contrast to anxiety, the studies of roles of postnatal 5-HT1A receptor 
on depression-like behavior and learning and memory are limited. Blockade of the 5-HT1A 
receptor during the postnatal period normalizes depression-like behavior in adult 5-HT 
transporter knockout mice (Alexandre et al., 2006). The role of the 5-HT1A receptor in the 
depression-like behavior is extensively studied, using 5-HT1A receptor knockout mice, in 
which the 5-HT1A receptor is blocked throughout the life. Many studies showed that 5-HT1A 
receptor knockout mice reduce depression-like behavior in adulthood (Parks et al., 1998; 
Ramboz et al., 1998; Richardson-Jones et al., 2010; Bortozzi et al., 2012; Ferres-Coy et al., 
2013; Piszszek et al., 2013). However, some studies also reported that the 5-HT1A 
receptor-overexpressed mice reduce depression-like behavior (Gunther et al., 2011) and the 
5-HT1A receptor knockout in heteroreceptor (vs. autoreceptor) increases depression-like 
behavior (Richardson-Jones et al., 2011). Therefore, the relationship between the 5-HT1A 
receptor and depression is somewhat controversial among studies. Regarding learning and 
memory, only a few studies have investigated using 5-HT1A receptor knockout mice. They 
show that blockade of the 5-HT1A receptor throughout the life impairs spatial learning and 
memory (Sarnyai et al., 2000; Wolff et al., 2004).  
  Taken together, in the present study I examined the roles of postnatal 5-HT and the 5-HT1A 
receptor on the formation of adult behaviors using pharmacological treatment with SSRI and 
5-HT1A receptor agonist. Next, I examined the effects of postnatal SSRI and the 5-HT1A 
receptor agonist on the expression of brain-derived neurotrophic factor (BDNF), the GABAA 
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receptor and the AMPA receptor in order to elucidate the underlying brain mechanisms. 
 
Brain-derived neurotrophic factor 
BDNF is a member of the neurotrophin family and binds to TrkB receptor, leading to 
dimerization and phosphorylation of the intracellular tyrosine kinase domain (Yoshii and 
Constantine-Paton, 2010). Subsequently, it triggers the activation of intracellular signaling 
cascades, including mitogen-activated protein kinase (MAPK), phosphatidyl inositol-3 kinase 
(PI3K), and phospholipase C (PLC)-γ pathways. In consequence, BDNF contributes to 
various functions in neuronal survival, cell migration, dendritic growth, synaptogenesis and 
synaptic plasticity (Park and Poo, 2013). 
  It is suggested that 5-HT and BDNF interact and cooperate with each other (Homberg et al., 
2014). For example, BDNF increases 5-HT synthesis in the 5-HT neuronal cell line RN46A 
and in the embryonic raphe culture in vitro (Eaton et al., 1995). BDNF also promotes the 
survival and sprouting of 5-HT axons in vivo (Mamounas et al., 1995). Conversely, 
enhancing 5-HT signaling, using monoamine oxidase (MAO) inhibitor, increases BDNF 
expression in the frontal cortex, while it decreases BDNF expression in the hippocampus 
(Zetterstrom et al., 1999). Hence, it is possible that changes of 5-HT system by treatment 
with SSRI and the 5-HT1A receptor agonist during the postnatal period may affect BDNF 
expression.  
  It has been also reported that BDNF is involved in depression-like behavior and learning 
and memory. Expression of BDNF is reduced in the brains of depressed patients (Castren and 
Kojima, 2107). In animal studies, both acute and chronic stresses decrease the expression of 
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BDNF in the cortex and hippocampus, whereas antidepressants increase the expression of 
BDNF to recover the stress-induced reduction of BDNF (Nestler, 2002). The relationship 
between BDNF and learning and memory is also extensively studied. Genetic and 
pharmacological deprivation of BDNF impairs hippocampus-dependent learning and memory 
(Yamada and Nabeshima, 2003).  
  Taken together, it is possible that BDNF is a candidate molecule linking postnatal 5-HT 
system and adult behaviors such as depression and spatial learning and memory. 
 
The GABAA receptor  
The GABAA receptor is a target of benzodiazepines, anxiolytics. Benzodiazepines have acute 
effects in the treatment of generalized anxiety disorder, social anxiety disorder, and panic 
disorder (Griebel and Holmes, 2013), whereas SSRIs show their effect after several weeks of 
treatment (Vaswani et al., 2003). The GABAA receptor has 19 subunits, which are α1-6, β1-3, 
γ1-3, δ, ε, θ, π, ρ1-3 (Rudolph and Knoflach, 2011). Among these subunits, benzodiazepines 
bind to one of the α subunits (α1, α2, α3, or α5) and a γ subunit, and drugs which target on 
the α2 or α3 subunit have already been made to clinical trials (Griebel and Holmes, 2013). 
Studies using rodents have suggested that the α2 and α3 subunits modulate anxiety-like 
behavior. The diazepam-induced anxiolytic effect is absent in mice with the point mutation of 
the α2 subunit, suggesting the anxiolytic effect is displayed via the α2 subunit (Low et al., 
2000). In addition, the selective agonist for the α3 subunit shows an anxiolytic effect (Dias et 
al., 2005) and the α3 subunit inverse agonist shows an anxiogenic effect in rats (Attack et al., 
2005).  
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The AMPA receptor 
In addition to the 5-HT system, glutamate receptor is known as a target of antidepressants. 
Recently, it was shown that ketamine has acute antidepressant activity (Murrough, 2012). 
Although SSRI requires a few weeks to show antidepressant effect, ketamine shows 
antidepressant effect in a few hours to several days. The glutamate receptor is comprised of 
the NMDA receptor, AMPA receptor, kainate receptor, and metabotropic glutamate receptor 
(mGluR). Ketamine potentiates the AMPA receptor in addition to the NMDA receptor 
antagonism, and the AMPA receptor has a crucial role in antidepressant effect (Koike and 
Chaki, 2014).  
  The AMPA receptor is a tetramer, which is composed of either GluR1, GluR2, GluR3, or 
GluR4 subunit, and most of the AMPA receptor is comprised of GluR1 and GluR2 (Derkach 
et al., 2007). The AMPA receptor usually permeates Na+, K+, and Ca2+, but a receptor with 
GluR2 subunit is not permeable to Ca2+. This characteristic is important in long-term 
potentiation (LTP) and long-term depression (LTD) (Huganir and Nicoll, 2013). LTP and 
LTD are controlled by the AMPA receptor trafficking between cell surface and cytoplasm. 
LTP is triggered by the transient increase of the AMPA receptors that has no GluR2 on the 
cell surface. This transient increase is caused by the phosphorylation of GluR1 and 
exocytosis of the AMPA receptors. On the other hand, LTD is triggered by the transient 
decrease of expression of the AMPA receptors on the cell surface. This transient decrease is 
caused by the phosphorylation of GluR2 and endocytosis of the AMPA receptors.  
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BALB/c mouse 
A single nucleotide polymorphism of tryptophan hydroxylase 2 (Tph2), 5-HT synthesizing 
enzyme, has been identified in BALB/c mice, and accordingly mRNA and protein levels of 
Tph2 in the dorsal raphe and protein level of 5-hydroxytryptophan, precursor of 5-HT, are 
decreased (Zhang et al., 2004; Siesser et al., 2010; Bach et al., 2011). Concomitantly, 5-HT 
level in the cerebral cortex and midbrain are decreased (Zhang et al., 2004; Bach et al., 2011). 
In addition, the mRNA expression of the 5-HT1A receptor is increased in the mPFC 
(unpublished observation) and the hypothalamus, although it is also reported that the protein 
level of 5-HT1A receptor are unchanged (Popova et al., 2009). The 5-HT2C receptor 
pre-mRNA editing, that is affected in depressed animals and patients (Gurevich et al., 2002; 
Iwamoto et al., 2005), is also altered in BALB/c mice (Englander et al., 2005; Hackler et al., 
2006). Besides the 5-HT system, BALB/c mice show increased level of anxiety, impairment 
of learning and memory, vulnerability to chronic stress, and high sensitivity to 
antidepressants (Francis et al., 2003; Brodkin, 2007; Uchida et al., 2011).  
  I used BALB/c mice in the present study, because I hypothesized that I could see more 
clearly the effects of SSRI and 5-HT1A receptor agonist on the behaviors.  
 
Purpose 
The roles of 5-HT and its receptors during the postnatal stages on the development of 
behavior are not well known. In this study, I examined the roles of 5-HT and the 5-HT1A 
receptor during the postnatal 3 weeks on the adult behavior. For this purpose, I treated 
postnatal mice with SSRI or the 5-HT1A receptor agonist. I first examined the adult behaviors, 
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such as anxiety, depression, spatial learning and memory, and pain sensitivity. Next, to 
elucidate the underlying brain mechanisms of anxiety and depression, I measured the mRNA 
expressions of the 5-HT1A receptor, BDNF, the GABAA receptor α2 and α3 subunits, and the 
AMPA receptor GluR1, and GluR2 subunits in the medial prefrontal cortex (mPFC), 
amygdala, and dorsal and ventral hippocampi during the postnatal period and the adulthood. 
By comparing the changes of behaviors with those of the mRNA expressions induced by 
SSRI and the 5-HT1A receptor agonist, it is possible to find some candidate genes, which may 
regulate adult behaviors. 
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MATERIALS AND METHODS 
 
Animals 
Pregnant female BALB/c mice (Japan SLC Inc., Shizuoka, Japan) were individually housed 
and maintained under a 12:12 h light/dark cycle (lights on 8:00AM) at 24oC, with food and 
water available ad libitum. The date of the birth was considered as postnatal day 0 (P0). Only 
male offspring were used. All the experiments were conducted in accordance with the Guide 
for the Care and Use of Laboratory Animals published by the National Institutes of Health 
(USA) and were approved by the Animal Experimentation Committee of the University of 
Tsukuba. 
 
Drug treatment 
Offspring were randomly assigned to 3 groups; control group, group of treatment with the 
selective 5-HT reuptake inhibitor (SSRI), and group of treatment with the 5-HT1A receptor 
agonist group. Pups from each group received an oral administration of 5% sucrose (or 
saline) (control), 5 mg/kg fluoxetine hydrochloride (a SSRI, Sigma-Aldrich, St. Louis, MO, 
USA), or 5 mg/kg (R)-(+)-8-hydroxy-DPAT hydrobromide (8-OH-DPAT) (Sigma-Aldrich) 
(5-HT1A receptor agonist), using a pipettor (Pipetman, Gilson, Middleton, WI, USA) with a 
small tip at its end, from P1 to P21. The dose of fluoxetine was decided on the basis of a 
previous study (Ishiwata et al., 2005). The dose of 8-OH-DPAT was determined by the 
evaluation of the concentration of 0.5 and 5 mg/kg in the anxiety-like behavior (Fig. 1).  
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Body weight 
Body weight of offspring were measured from P1 to P21 during the drugs were administered 
and at P71 when the brains were removed. 
 
Elevated plus maze (EPM) 
All behavioral tests were conducted from postnatal week 9 to 10. To investigate the effects 
on the anxiety-like behavior, the offspring of each experimental group were tested on P57 
using the EPM (Ohara & Co., Ltd., Tokyo, Japan). The apparatus was elevated 60 cm from 
the floor and consisted of two opposing open arms (25 cm length x 5 cm width x 0.3 cm 
height) and two opposing closed arms (25 cm x 5 cm x 15 cm) that were connected by a 
central platform (6 cm x 6 cm). Each animal was placed in the central platform, facing a 
closed arm. All animals were tested once between 10:00 and 13:00, under regular room light 
(360 lux). The behavior was recorded for 5 min by use of an overhead color CCD camera. 
The time spent in the open arms and the number of entries into open arms were calculated as 
indices of anxiety-like behavior. 
 
Morris water maze (MWM) 
On P59-P65, the spatial learning and memory of the offspring of each experimental group 
was examined using the MWM (Ohara & Co., Ltd., Tokyo, Japan). The maze consisted of a 
circular pool (100 cm diameter and 30 cm depth) filled with water (22 ± 1 oC) colored by 
white poster color. A transparent escape platform (10 cm diameter) was situated 15 cm away 
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from the side wall and hidden 1 cm below the water surface. A series of tests was conducted 
between 9:30 and 13:00, under regular room light (450 lux). During the 5 day-course of the 
training, the platform was placed in a stable position that was centered in one of the four 
quadrants of the pool. Each daily session consisted of 3 trials in which animals were forced to 
swim from each of three random starting positions. They were allowed to search for the 
hidden platform for up to 90 sec, and remained on the platform for 30 sec after reaching it. 
Animals, which did not reach the platform, were moved onto the platform to rest for 30 sec. 
On day 6, mice were subjected to a probe test in which the platform was removed from the 
pool, and the mice were allowed to swim freely for 90 sec. The time spent in the quadrant 
where the platform had been located was measured. On day 7, a cued test was carried out 
during which the platform was changed to one that has a visible black box above the water 
surface and the time it took animals to reach it was measured. 
 
Hot plate test 
On P67, the pain sensitivity of the offspring of each experimental group was tested using the 
hot plate test (Ugo Basile, Monvalle VA, Italy). Each mouse was placed on the hot plate 
(54 °C) and the reaction time to lick or rub paws, jump, or shack the body was measured. 
 
Forced swim test (FST) 
Depression-like behavior was assessed as previously described (Porsolt et al., 1977) with 
slight modifications. The offspring of each experimental group were tested on P69 using the 
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FST. All animals were tested between 12:00 and 14:00, under regular room light (360 lux). 
Each animal was placed into the water (23 ± 1 oC) (7-cm height) in a 4L beaker (20-cm 
diameter). The behavior was analyzed during the last 4 min of the 6-min testing period. The 
first 2 min were considered as habituation. The time spent floating on the water surface 
without any movement except for minimal activity that the mouse kept them from drowning, 
was measured as an index of depression-like behavior. The time spent climbing was recorded 
when vigorous vertical movements with the forepaws against the wall of the beaker were 
displayed. Swimming time was calculated by subtraction of the floating and climbing times 
from the total testing period. 
 
Sucrose preference test (SPT) 
For the SPT, the offspring were acclimatized to two identical drinking bottles, one filled with 
2% sucrose solution and the other with water, for 4 hr/day for 4 days. After overnight water 
deprivation, the SPT was conducted for 4 hr on the day 5. To avoid the side preference, the 
positions of the bottles were switched after 2 hr and interchanged daily. Sucrose and water 
consumption were determined by measuring the change in the volume of fluid consumed. 
Sucrose preference was defined as the ratio of the volume of sucrose versus total volume of 
sucrose and water consumed during the 4-hr test. 
 
Brain Dissection 
Under anesthesia by isoflurane, the mice were decapitated and their brains were quickly 
removed at P22 and P71. 2 mm thick coronal slices were cut on ice from the frontal pole of 
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the cerebral cortex using a Mouse Brain Matrix (Muromachi Kikai Co., Ltd., Tokyo, Japan), 
and the left hemisphere was used for the analysis of the expression of mRNA. The mPFC 
(Leuner and Shors, 2013) was punched out from the first slice and the amygdala was punched 
out from the third slice using a Harris Micro-Punch (GE healthcare, buckinghamshir, UK). 
The dorsal and ventral halves of the hippocampus were dissected out from the third and forth 
slices using a Noyes surgical scissor. We divided the hippocampus into dorsal and ventral 
halves because these regions have been shown to be involved in cognition and emotion, 
respectively (Bannerman et al., 2004). 
 
Real-time reverse transcription-PCR 
Each region was homogenized in RNAiso (Takara Bio, Shiga, Japan) and total RNA was 
isolated using RNAiso (Takara Bio), according to the manufacturer’s instructions. The 
isolated 1 µg of total RNA was reverse-transcribed using the QuantiTect Reverse 
Transcription kit (Qiagen, Hilden, Germany). PCR was performed using the Thermal Cycler 
Dice Real Time TP800 System (Takara Bio) with SYBR Premix Ex Taq II (Takara Bio). The 
thermal cycling conditions comprised an initial step at 95°C for 10 sec, followed by 50 cycles 
at 95°C for 5 sec and at 60°C for 30 sec. Table 1 lists the primer sequences. The primers used 
in the present study are designed to capture all the splicing variants. The 5-HT1A receptor, 
GABAA receptor α2 and α3 subunits, and 18S rRNA genes do not have any splicing variants. 
The sizes of the PCR products were verified using agarose gel electrophoresis. Quantitation 
was performed using the crossing point method. The data was normalized to 18S rRNA. 
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Statistical analysis 
SPSS (SPSS Inc., Japan) was used for statistical analysis. Analyses of training of MWM and 
body weight from P1 to P21 were performed using repeated measures analysis of variance 
(ANOVA), with day as the within-subject factor and experiment group as between-subject 
factor, followed by student’s t test (training of MWM) or one-way ANOVA (body weight). 
For evaluations of probe test and cued test of MWM and hot plate test, data were analyzed by 
student’s t test. For evaluation of body weight at P71, EPM, FST, SPT, and mRNA 
expression, data were analyzed by one-way ANOVA, followed by post hoc analysis (Fisher’s 
protected least significant difference test). For the evaluation of correlation between the 
mRNA expression of the 5-HT1A receptor and BDNF at P71, Pearson’s test was performed. p 
< 0.05 was considered as statistically significant. All data are expressed as mean ± S.E.M. 
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RESULTS 
 
Postnatal 8-OH-DPAT treatment showed anxiolytic effects at the concentration of 5 
mg/kg 
The concentration of 8-OH-DPAT was determined by evaluating effects on the anxiety-like 
behavior using the EPM, since the previous studies reported that blockade of the 5-HT1A 
receptor during postnatal period increased anxiety-like behavior in adulthood (Gross et al., 
2002; Vinkers et al., 2010). ANOVA revealed marginally significant main effects on the time 
spent in open arms (F(2,30) = 3.129, p = 0.058) (Fig. 1A) and the ratios of entries into open 
arms (F(2,30) = 2.917, p = 0.07) (Fig. 1B), but not for the total number of entries into both 
open and closed arms (F(2,30) = 0.722, p = 0.494) (Fig. 1C). Post hoc test showed that mice 
treated with 5 mg/kg 8-OH-DPAT increased the time spent in open arms (p < 0.05) and the 
ratios of entries into open arms (p < 0.05). On the other hand, mice treated with 0.5 mg/kg 
8-OH-DPAT showed no changes in the time spent in the open arms (p = 0.827) and the ratios 
of entries into open arms (p = 0.311). Thus, I treated with 8-OH-DPAT at the concentration 
of 5 mg/kg for the further analyses. 
 
Postnatal treatment with fluoxetine and 8-OH-DPAT did not alter body weight 
During the treatment with fluoxetine and 8-OH-DPAT from P1 to P21, main day effect on 
the body weight was significant (F(20,1960) = 2624.008, p < 0.001), but the interaction 
between day and group was not significant (F(2,98) = 1.95, p = 0.148) (Table 2). At P71, 
ANOVA revealed no significant main effects on the body weight (F(2,38) = 0.175, p = 0.84). 
Thus, the drug treatment had no effect on the body weight. 
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Postnatal treatment with fluoxetine and 8-OH-DPAT decreased anxiety-like behavior in 
adulthood 
I examined effects of postnatal treatment with fluoxetine and 8-OH-DPAT on anxiety-like 
behavior in adulthood, using the EPM (Fig. 2). ANOVA revealed significant main effects on 
the time spent in open arms (F(2,38) = 8.788, p < 0.001) (Fig. 2A), the ratios of entries into 
open arms (F(2,38) = 9.152, p < 0.001) (Fig. 2B), and total number of entries into both open 
and closed arms (F(2,38) = 4.104, p < 0.05) (Fig. 2C). The post hoc test showed that 
postnatal treatment with both fluoxetine and 8-OH-DPAT increased the time spent in open 
arms (fluoxetine, p < 0.01; 8-OH-DPAT, p < 0.001) (Fig. 2A) and the entries into open arms 
(fluoxetine, p < 0.001; 8-OH-DPAT, p < 0.01) (Fig. 2B), as compared with the control mice. 
In addition, postnatal 8-OH-DPAT treatment decreased the total number of entries into both 
open and closed arms (p < 0.01), whereas fluoxetine treatment had no effect, as compared 
with the control mice (p = 0.103) (Fig. 2C). 
 
Postnatal 8-OH-DPAT treatment increased depression-like behavior in adulthood 
Next, I used the FST (Fig. 3) and the SPT (Fig. 4) to examine the effects of postnatal 
treatment with fluoxetine and 8-OH-DPAT on depression-like behavior in adulthood. 
According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-V), major 
depressive disorder in humans is defined by depressed mood (behavioral despair) or a loss of 
interest or pleasure (anhedonia) in daily activities. Therefore, I used the FST to measure 
behavioral despair (Porsolt et al., 2001) and the SPT to measure anhedonia (Papp et al., 
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1991). 
  In the FST, ANOVA revealed significant main effects on the floating (F(2,37) = 5.069, p < 
0.05) (Fig. 3A), swimming (F(2,37) = 6.841, p < 0.01) (Fig. 3B), and the climbing (F(2,37) = 
4.851, p < 0.05) (Fig. 2C) times. Postnatal 8-OH-DPAT treatment increased the floating time 
(p < 0.01) (Fig. 3A), whereas it decreased the swimming (p < 0.01) (Fig. 3B) and climbing (p 
< 0.01) (Fig. 3C) times. Postnatal fluoxetine treatment had no effects on any parameters: the 
floating (p = 0.62) (Fig. 3A), the swimming (p = 0.714) (Fig. 3B), and the climbing (p = 
0.489) (Fig. 3C) times. 
  In the SPT, ANOVA revealed no significant main effect on the sucrose preference (F(2,38) 
= 0.466, p = 0.631) (Fig. 4).  
 
Postnatal treatment with fluoxetine and 8-OH-DPAT had no effects on spatial learning 
and memory in adulthood 
I examined the effects of postnatal fluoxetine and 8-OH-DPAT on adult spatial learning and 
memory in adulthood by the MWM (Figs. 5, 6). In the 5 days-training of MWM, the main 
day effects were significant (fluoxetine, F(4,52) = 13.065, p < 0.001; 8-OH-DPAT, F(4,76) = 
18.435, p < 0.001), but the interactions between day and group were not significant 
(fluoxetine, F(4,52) = 0.864, p = 0.49; 8-OH-DPAT, F(4,76) = 1.168, p = 0.323) (Figs. 5A, 
6A). The probe test showed no significant effects on the time spent in the platform quadrant 
(fluoxetine, t(13) = -1.053, p = 0.312; 8-OH-DPAT, t(19) = -0.786, p = 0.441) and the 
number of crossing of the platform (fluoxetine, t(13) = -1.332, p = 0.206; 8-OH-DPAT, t(19) 
= -1.334, p = 0.198) (Figs. 5B, 6B). The cued test also showed no significant effects 
(fluoxetine, t(13) = 0.355, p = 0.728; 8-OH-DPAT, t(19) = -0.159, p = 0.876) (Figs. 5C, 6C). 
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Postnatal treatment with fluoxetine and 8-OH-DPAT had no effect on pain sensitivity in 
adulthood 
I examined the effects of postnatal fluoxetine and 8-OH-DPAT on adult pain sensitivity by 
the hot plate test. Neither postnatal fluoxetine nor 8-OH-DPAT affected the reaction time 
(fluoxetine, t(16) = -1.179, p = 0.256; 8-OH-DPAT, t(29) = 0.829, p = 0.414) (Fig. 7). 
 
Postnatal 8-OH-DPAT treatment decreased the mRNA expression of the 5-HT1A 
receptor in the mPFC and the reduction was maintained in adulthood 
As described above, postnatal treatment with fluoxetine and 8-OH-DPAT induced significant 
changes in anxiety and/or depression-like behaviors in adulthood. To elucidate the brain 
mechanisms underlying the effects on behaviors, I examined gene expression focusing on the 
genes and brain regions, which are reported to relate with anxiety and depression. 
  In order to investigate the chronic effects of fluoxetine and 8-OH-DPAT, I measured the 
mRNA expression of the 5-HT1A receptor at P22 and at P71 (Fig. 8). ANOVA revealed 
significant main effects on the mRNA expression of the 5-HT1A receptor at P22 in the mPFC 
(F(2,23) = 4.228, p < 0.05), dorsal hippocampus (F(2,22) = 6.061, p < 0.01), and ventral 
hippocampus (F(2,23) = 5.017, p < 0.05), but not in the amygdala (F(2,19) = 2.548, p = 
0.105) (Fig. 8A). The treatment with fluoxetine and 8-OH-DPAT between P1 and P21 
decreased the mRNA expression of the 5-HT1A receptor in the mPFC (fluoxetine, p < 0.05; 
8-OH-DPAT, p < 0.05) and ventral hippocampus (fluoxetine, p < 0.05; 8-OH-DPAT, p < 
0.01). 8-OH-DPAT treatment also decreased the mRNA expression of the 5-HT1A receptor in 
the dorsal hippocampus (p < 0.01). 
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  In contrast, ANOVA revealed a significant main effect on the mRNA expression of the 
5-HT1A receptor at P71 in the mPFC (F(2,20) = 5.369, p < 0.05), but not in the amygdala 
(F(2,18) = 1.626, p = 0.224), dorsal hippocampus (F(2,18) = 2.057, p = 0.157) or ventral 
hippocampus (F(2,18) = 0.652, p = 0.533) (Fig. 8B). 8-OH-DPAT treatment decreased the 
mRNA expression of the 5-HT1A receptor in the mPFC at P71 (p < 0.05). 
 
Postnatal 8-OH-DPAT treatment decreased the mRNA expression of BDNF in the adult 
mPFC 
Next, I examined the mRNA expression of BDNF at P22 and P71 (Fig. 9). ANOVA revealed 
a marginally significant main effects on the mRNA expression of BDNF at P22 in the mPFC 
(F(2,23) = 3.132, p = 0.063), but not in the amygdala (F(2,16) = 0.103, p = 0.903), dorsal 
hippocampus (F(2,20) = 2.05, p = 0.155), or ventral hippocampus (F(2,24) = 1.799, p = 
0.187) (Fig. 9A). The post-hoc test revealed that the treatments with fluoxetine and 
8-OH-DPAT during the postnatal period decreased the mRNA expression of BDNF in the 
mPFC at P22 (fluoxetine, p < 0.05; 8-OH-DPAT, p < 0.05) (Fig. 9A). 
  In contrast, ANOVA revealed a significant main effect on the mRNA expression of BDNF 
at P71 in the mPFC (F(2,23) = 11.411, p < 0.001), but not in the amygdala (F(2,18) = 1.769, 
p = 0.199), dorsal hippocampus (F(2,16) = 0.323, p = 0.728), or ventral hippocampus 
(F(2,16) = 2.658, p = 0.101) (Fig. 9B). 8-OH-DPAT treatment during the postnatal period 
decreased the mRNA expression of BDNF in the mPFC at P71 (p < 0.001). 
 
Postnatal 8-OH-DPAT treatment decreased the mRNA expression of the GABAA 
receptor α2 subunit in the adult mPFC and ventral hippocampus 
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I measured the mRNA expression of the GABAA receptor α2 subunit at P71 (Fig. 10A). 
ANOVA revealed significant main effects on the mRNA expression of GABAA receptor α2 
subunit in the mPFC (F(2,16) = 8.646, p < 0.01), dorsal hippocampus (F(2, 20) = 4.546, p < 
0.05) and ventral hippocampus (F(2,17) = 9.782, p < 0.001), but not in the amygdala (F(2,18) 
= 0.028, p = 0.973). 8-OH-DPAT treatment during the postnatal period decreased the mRNA 
expression of the GABAA receptor α2 subunit in the mPFC and the ventral hippocampus 
(mPFC, p < 0.01; ventral hippocamous, p < 0.01). In addition, 8-OH-DPAT treatment during 
the postnatal period decreased the mRNA expression of the GABAA receptor α2 subunit in 
the dorsal hippocampus, as compared with the treatment with fluoxetine (p < 0.01). 
 
Postnatal treatment with fluoxetine and 8-OH-DPAT decreased the mRNA expression 
of the GABAA receptor α3 subunit in the adult mPFC and ventral hippocampus 
I measured the mRNA expression of the GABAA receptor α3 subunit at P71 (Fig. 10B). 
ANOVA revealed significant main effects on the mRNA expression of GABAA receptor α3 
subunit in the mPFC (F(2,23) = 10.996, p < 0.001), amygdala (F(2,16) = 6.889, p < 0.01) and 
ventral hippocampus (F(2,19) = 5.882, p < 0.01), but not in the dorsal hippocampus (F(2,18) 
= 1.876, p = 0.182). Both the treatment with fluoxetine and 8-OH-DPAT during the postnatal 
period decreased the mRNA expression of the GABAA receptor α3 subunit in the mPFC 
(fluoxetine, p < 0.01; 8-OH-DPAT, p < 0.001) and ventral hippocampus (fluoxetine, p < 
0.05; 8-OH-DPAT, p < 0.01). In addition, only the treatment with fluoxetine decreased the 
mRNA expression of the GABAA receptor α3 subunit in the amygdala (p < 0.01). 
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Postnatal treatment with fluoxetine and 8-OH-DPAT did not affect the mRNA 
expression of GluR1 and GluR2 in adulthood 
I measured the mRNA expression of GluR1 and GluR2 at P71 as presumptive mediators of 
depression-like behavior (Fig. 11). ANOVA revealed a significant main effect on the mRNA 
expression of GluR1 in the ventral hippocampus (F(2,22) = 3.675, p < 0.05) and a marginally 
significant main effect in the mPFC (F(2,19) = 3.211, p = 0.063), but not in the dorsal 
hippocampus (F(2,17) = 0.12, p = 0.888) (Fig. 11A). The treatment with fluoxetine increased 
the mRNA expression of GluR1 in the ventral hippocampus and decreased in the mPFC, as 
compared with the treatment with 8-OH-DPAT (p < 0.05). ANOVA revealed no significant 
main effects on the mRNA expression of GluR2 in the mPFC (F(2,19) = 1.666, p = 0.215) or 
the dorsal (F(2,18) = 0.319, p = 0.731) and ventral hippocampi (F(2,21) = 0.206, p = 0.816) 
(Fig. 11B).  
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DISCUSSION 
 
Early-life experiences are known to alter brain structures and functions in later life. 
Dysfunction of 5-HT and the 5-HT1A receptor during development is closely related to the 
alterations of behaviors in adulthood (Daubert and Condron, 2010). The present study 
showed that treatment with fluoxetine and 8-OH-DPAT between P1 and P21 decreased 
anxiety-like behavior in adulthood, while the same postnatal 8-OH-DPAT treatment 
increased depression-like behavior in terms of behavioral despair in adulthood (Table 3). 
There were no significant effects of fluoxetine and 8-OH-DPAT on the spatial learning and 
memory and pain sensitivity. To elucidate the brain mechanisms that regulate anxiety and 
depression, we examined the fluoxetine and 8-OH-DPAT-induced changes in the mRNA 
expression (Tables 4, 5). Both the treatment with fluoxetine and 8-OH-DPAT decreased the 
mRNA expression of the GABAA receptor α3 subunit in the mPFC and the ventral 
hippocampus (Table 5). In contrast, only the 8-OH-DPAT treatment decreased the mRNA 
expression of the 5-HT1A receptor and BDNF in the mPFC and the GABAA receptor α2 
subunit in the mPFC and the ventral hippocampus in adulthood. Therefore, we found some 
correlative changes between adult anxiety and depression and the mRNA expression of the 
GABAA receptor α subunits and BDNF in response to postnatal treatment with fluoxetine and 
8-OH-DPAT. 
 
Effects of postnatal treatment with fluoxetine and 8-OH-DPAT on body weight  
5-HT regulates food intake (Voigt and Fink, 2015) and it was reported that acute and chronic 
treatment with fluoxetine decreased food intake and body weight in the adult rodents (Yen 
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and Fuller, 1992). A previous clinical study reported that prenatal SSRI exposure through 
depressed mother’s milk increased preterm birth and decreased birth weight (Olivier et al., 
2011). However, the present study showed that treatment with fluoxetine and 8-OH-DPAT 
during the postnatal period had no effects on the body weight of the mice throughout the life. 
Thus, it is suggested that fluoxetine and 8-OH-DPAT during the postnatal period had no 
effects on the food intake and the growth of the mice’ bodies. 
 
Effects of postnatal treatment with fluoxetine and 8-OH-DPAT on anxiety-like behavior 
in adulthood 
SSRI is widely used as an antidepressant for adult patients and has both antidepressant and 
anxiolytic effects in adult mice (Olivier et al., 2011). In contrast, the effects of SSRI 
administration during the development are controversial. Long-term effects of prenatal and 
postnatal SSRI administration have been studied in rodents. Some studies reported that SSRI 
administration during the prenatal and postnatal periods increases both anxiety (Ansorge et 
al., 2004; Rebello et al., 2014; Sarkar et al., 2014) and depression-like behaviors (Karpova et 
al., 2009; Ko et al., 2014; Rebello et al., 2014; Sarkar et al., 2014), whereas others reported 
no changes (Kiryanova et al., 2013). This may be due to the differences in methods used, 
such as dosage (ranging from 0.3 mg/kg/day to 25 mg/kg/day) of SSRI and methods of 
administration (Kiryanova et al., 2013). Interestingly, several studies reported beneficial 
effects of the postnatal SSRI administration in the prenatally stressed animals (Ishiwata et al., 
2005; Nagano et al., 2012; Rayen et al., 2015; Boulle et al., 2016). Thus, fluoxetine 
administration decreased anxiety-like behavior in the prenatally stressed rats, although the 
same treatment showed no or even increased changes of anxiety-like behavior in the 
 31 
non-stressed rats (Nagano et al., 2012; Boulle et al., 2016). In addition, fluoxetine 
administration decreased the number of immature neurons and increased the densities of 
spine and synapse in the hippocampus in the prenatally stressed rodents, although fluoxetine 
administration increased the number of immature neurons and decreased the densities of 
spine and synapse in the hippocampus in non-stressed rodents (Ishiwata et al., 2005; Rayen et 
al., 2015).  
  The present study showed that fluoxetine treatment during the postnatal period decreased 
anxiety-like behavior of BALB/c mice. It has been reported that BALB/c mice show 
increased level of anxiety and vulnerability to chronic stress (Francis et al., 2003; Uchida et 
al., 2011). In addition, BALB/c mice are sensitive to chronic fluoxetine treatment and show 
anxiolytic/antidepressant responses in adult (Dulawa et al., 2004; Popa et al., 2010), similar 
to human cases in which antidepressants are effective in patients with higher anxiety or 
depression, but not so effective in healthy individuals (Barr et al., 1997; Gelfin et al., 1998). 
Thus, fluoxetine treatment during the postnatal period may have had beneficial effects in 
BALB/c mice in the present study. However, further studies are needed to elucidate the 
underlying mechanism of the beneficial effects in BALB/c mice in the present study. Popa et 
al. have shown that 5-HT levels in the raphe and the hippocampus are increased in response 
to chronic fluoxetine treatment and desensitization of the 5-HT1A autoreceptor particularly 
plays an important role in anxiolytic effects in adult BALB/c mice (Popa et al., 2010). 
However, it still remains to be elucidated how SSRI administration during the development 
affects 5-HT levels and 5-HT receptors.   
	 The present study showed that both fluoxetine and 8-OH-DPAT during the postnatal 
period decreased anxiety-like behavior in adulthood. Therefore, it is possible that among 
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5-HT receptors, 5-HT1A receptor may mediate the postnatal SSRI treatment-induced decrease 
in anxiety levels in adulthood. The role of the 5-HT1A receptor in decreasing anxiety is 
consistent with previous studies on postnatal treatment with the 5-HT1A receptor antagonist 
(Vinkers et al., 2010) and 5-HT1A receptor knockout and knockdown mice (Gross et al., 
2002; Donaldson et al., 2014). Both 5-HT1A receptor antagonist treatment from P0 to P21 and 
conditional knockout of heteroreceptor and knockdown of 5-HT1A autoreceptor until P21 
increased adult anxiety-like behavior (Gross et al., 2002; Vinkers et al., 2010). Therefore, the 
present activation study also suggested that postnatal 5-HT1A receptor down-regulates the 
development of anxiety. Further studies are needed to determine autoreceptors or 
heteroreceptors of 5-HT1A receptors are involved in the anxiety. 
 
Effects of postnatal 8-OH-DPAT treatment on depression-like behavior in adulthood 
In contrast to the effect on anxiety, the present study showed that postnatal 8-OH-DPAT 
treatment increased depression-like behavior. This result is in agreement with a previous 
study that blockade of the 5-HT1A receptor during the development alleviates depression-like 
behavior in adulthood (Alexandre et al., 2006).  
	 The 5-HT1A receptor is one of the main targets as the treatment of major depressive 
disorder. Buspirone, the 5-HT1A receptor partial agonist, and vilazodone, potent SSRI and the 
5-HT1A receptor partial agonist are already approved for clinical uses as antidepressants 
(Sahli et al., 2016). In the present study, 8-OH-DPAT treatment during the postnatal period 
showed increase of depression-like behavior as well as decrease of the 5-HT1A receptor 
mRNA expression in the mPFC at P71. In contrast to the anti-depressive effects during the 
adulthood, the 5-HT1A receptor during the postnatal period acted oppositely on the 
 33 
depression-like behavior in the present study. A previous study has reported that blockade of 
the 5-HT1A receptor during the development decreases depression-like behavior in adulthood 
(Alexandre et al., 2006). In addition, most previous studies using 5-HT1A receptor knockout 
mice have shown the reduced level of depression in adults (Parks et al., 1998; Ramboz et al., 
1998; Richardson-Jones et al., 2010; Bortozzi et al., 2012; Ferres-Coy et al., 2013; Piszszek 
et al., 2013). These results suggest that the 5-HT1A receptor has different effects on the 
depression-like behavior, depending on the age. 
  Taken together, these findings suggest that the activation (or blockade) of the 5-HT1A 
receptor during the postnatal period decreases (or increases) anxiety-like behavior but 
increases (or decreases) depression-like behavior in adulthood. Anxiety and depression are 
often comorbid, but these findings suggest that these two disorders are caused by different 
mechanisms (see also Ressler and Nemeroff, 2000; Leonardo and Hen, 2008). 
 
Effects of postnatal 8-OH-DPAT treatment on the mRNA expression of the 5-HT1A 
receptor 
In the present study, the postnatal treatment with 8-OH-DPAT decreased the mRNA 
expression of the 5-HT1A receptor both in the mPFC and in the hippocampus at P22, but this 
reduction in the mRNA expression of the 5-HT1A receptor persisted until P71 in the mPFC, 
but not in the hippocampus. A previous study showed that environmental factors during the 
perinatal period such as prenatal stress and postnatal brief maternal separation (handling) 
modulated the mRNA expression of 5-HT receptors in the offspring’s hippocampus during 
the postnatal period, but not in adulthood, while the effects remained observed in the adult 
frontal cortex (Akatsu et al., 2015). These results suggest that the effects on 5-HT receptor 
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expression are maintained in the frontal cortex throughout life while the hippocampus may 
have plasticity to recover the changes. 
  The present study showed that postnatal treatment with 8-OH-DPAT decreased the mRNA 
expression of the 5-HT1A receptor in the mPFC at P71, and concomitantly increased 
depression-like behavior in adulthood. On the basis of the correlations between the mRNA 
expression and behavior in adulthood, it is possible that the 5-HT1A receptor in the adult 
mPFC may modulate depression-like behavior, which is supported by the previous studies 
(Kato et al, 2015; Sahli et al., 2016). The 5-HT1A receptor is one of the main targets for the 
treatment of major depressive disorder in adult. Kato et al. (2015) reported that DSP-1053, a 
novel SSRI with 5-HT1A receptor agonistic activity shows antidepressant effects in adults. In 
addition, buspirone, 5-HT1A receptor partial agonist, and vilazodone, potent SSRI with 
5-HT1A receptor partial agonistic activity, have already been approved for clinical use, as 
antidepressants in adults (Sahli et al., 2016). Taken together, the present findings suggest that 
the 5-HT1A receptor has opposite effects on the depression between the postnatal period and 
adulthood. Specifically, the activation of the 5-HT1A receptor in adulthood ameliorates 
depression-like behavior, whereas the similar activation of the 5-HT1A receptor during the 
postnatal period induces depression-like behavior in adulthood. 
 
Effects of postnatal 8-OH-DPAT treatment on the mRNA expression of BDNF 
In the present study, 8-OH-DPAT decreased the mRNA expression of BDNF in the mPFC at 
P71 and concomitantly increased adult depression-like behavior in adulthood. Besides the 
5-HT1A receptor, many studies including postmortem studies, pharmacological studies using 
antidepressants, and BDNF polymorphism studies have reported strong correlation between 
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reduced BDNF signaling in the adult prefrontal cortex and hippocampus and depression 
(Dwivedi, 2009). In addition, functional association between the 5-HT1A receptor and BDNF 
has been suggested. The 5-HT1A receptor is linked to mitogen-activated protein kinase 
(MAPK) signaling pathway, and the activation of the cyclic adenosine monophosphate 
(cAMP) response element binding protein (CREB) in the MAPK signaling pathway 
upregulates the expression of BDNF in adulthood (Polter and Li, 2010; Homberg et al., 2014). 
Indeed, the present study showed a positive correlation between the mRNA expression of the 
5-HT1A receptor and BDNF in the adult mPFC (r = 0.664, p < 0.001) (Fig. 12). Therefore, 
reduced 5-HT1A receptor in adulthood possibly downregulates the expression of BDNF in the 
mPFC, which induces depression-like behavior. 
 
Effects of postnatal 8-OH-DPAT treatment on the mRNA expression of the GABAA 
receptor α2 subunit 
In addition to the 5-HT1A receptor and BDNF, the present study showed that postnatal 
treatment with fluoxetine and 8-OH-DPAT affected the mRNA expression of the GABAA 
receptor α subunits. In particular, 8-OH-DPAT treatment reduced the mRNA expression of 
the GABAA receptor α2 subunits in the adult mPFC and ventral hippocampus. Considering 
that postnatal 8-OH-DPAT treatment increased adult depression-like behavior, this finding 
suggests that the reduction of the GABAA receptor α2 subunits in the adult mPFC and ventral 
hippocampus may be involved in the 8-OH-DPAT-induced increase in depression-like 
behavior. This idea was supported by studies reporting that depression-like behavior is 
increased in GABAA receptor α2 subunit knockout mice (Rudolph and Knoflach, 2011; 
Vollenweider et al., 2011). In addition, the GABAA receptor α2 subunit is involved in adult 
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neurogenesis in the dentate gyrus of the hippocampus (Duveau et al., 2011). Since 
antidepressants promote adult neurogenesis (Malberg et al., 2000), it is possible that the 
GABAA receptor α2 subunit in the ventral hippocampus affects depression-like behavior 
through adult neurogenesis. 
 
 
Effects of postnatal treatment with fluoxetine and 8-OH-DPAT on the mRNA 
expression of the GABAA receptor α3 subunit  
The present study also showed that postnatal treatment with both fluoxetine and 8-OH-DPAT 
decreased the mRNA expression of the GABAA receptor α3 subunit in the adult mPFC and 
ventral hippocampus. In addition, both treatments decreased anxiety levels in adulthood. On 
the basis of the correlative changes of mRNA expression and behavior, the reduction of the 
GABAA receptor α3 subunit in the adult mPFC and ventral hippocampus may decrease 
anxiety levels. By treating GABAA receptor α2 subunit mutated mice with the GABAA 
receptor α3 subunit agonist, Dias et al. demonstrated that the GABAA receptor α3 subunit is 
more effective in mediating anxiolytic action than is the GABAA receptor α2 subunit (Dias et 
al., 2005). However, the changes in the mRNA expression of the GABAA receptor α3 subunit 
in the mPFC and ventral hippocampus and anxiety-like behavior in the present study were 
not consistent with those shown in previous studies (Attack et al., 2005; Dias et al., 2005). 
Those studies showed that activation of the GABAA receptor α3 subunit has an anxiolytic 
effect (Dias et al., 2005), whereas suppression of the GABAA receptor α3 subunit has an 
anxiogenic effect (Attack et al., 2005). The discrepancy between the present and previous 
studies suggests that the GABAA receptor α3 subunit in the mPFC and ventral hippocampus 
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may not play a critical role in the anxiolytic effect by fluoxetine and 8-OH-DPAT. It is 
possible that activation of the GABAA receptor α3 subunit in brain regions other than that of 
the mPFC and ventral hippocampus is required for the anxiolytic effect. In addition, in the 
present study, postnatal fluoxetine treatment, but not 8-OH-DPAT treatment, decreased the 
mRNA expression of the GABAA receptor α3 subunit in the amygdala. Therefore, other 5-HT 
receptors than the 5-HT1A receptor might mediate the reduction of the GABAA receptor α3 
subunit in the amygdala. 
 
Effects of postnatal treatment with fluoxetine and 8-OH-DPAT on the mRNA 
expression of the GluR1 and GluR2 
The GluR1 and GluR2 subunits of AMPA receptors were reported to modulate depression 
(Martinez-Turrillas et al., 2002; Tan et al., 2006). However, the present study showed no 
significant changes in the mRNA expression of the GluR1 and GluR2 induced by 
8-OH-DPAT treatment, which increased the depression-like behavior. Therefore, the 5-HT1A 
receptor agonist during the postnatal period may induce depression-like behavior, 
independently of the GluR1 or GluR2 expression in the mPFC and the hippocampus. 
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CONCLUSION  
 
The effects of 5-HT and the 5-HT1A receptor during the postnatal period on the adult 
behaviors and the underlying mechanisms were largely unknown. In the present study, I 
showed that 5-HT during the postnatal period had an anxiolytic effect in adulthood, probably 
via the 5-HT1A receptor during the postnatal period. In contrast, postnatal activation of the 
5-HT1A receptor induced depression-like behavior in adulthood. By comparing the behavioral 
effects and the changes in mRNA expression, I found that postnatal 5-HT and the 5-HT1A 
receptor may decrease adult anxiety-like behavior by reducing the GABAA receptor α3 
subunit in the mPFC and ventral hippocampus in adulthood. On the other hand, the 5-HT1A 
receptor during the postnatal period may increase adult depression-like behavior by reducing 
the 5-HT1A receptor and BDNF in the mPFC and the GABAA receptor α2 subunit in the 
mPFC and the ventral hippocampus in adulthood. Although the direct causal relationship 
between the gene expressions and the behaviors remain to be examined, the present study 
may give a clue to understanding the mechanisms of anxiety and depression affected by 5-HT 
and the 5-HT1A receptor during the postnatal period. 
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Figure 1.  8-OH-DPAT concentration 
Anxiety-like behavior in the elevated plus maze test  in mice treated with saline, 0.5 mg/
kg 8-OH-DPAT, and 5 mg/kg 8-OH-DPAT from P1-P21. (A) Percentage of the time 
spent in the open arms. (B) Percentage of numbers of entries into open arms. (C) Total 
numbers of entries. Each bar represents the mean ± S.E.M (n=15 for control, n=7 for 0.5 
mg/kg 8-OH-DPAT, n=11 for 5 mg/kg 8-OH-DPAT). * p < 0.05  
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Figure 2  Anxiety-like behavior 
Anxiety-like behavior in the elevated plus maze test in mice treated with sucrose, 
fluoxetine, or 8-OH-DPAT from P1-P21. (A) Percentage of the time spent in the open 
arms. (B) Percentage of numbers of entries into open arms. (C) Total numbers of entries. 
Each bar represents the mean ± S.E.M (n=13 for control, n=14 for fluoxetine, n=14 for 
8-OH-DPAT). ** p < 0.01, *** p < 0.001  
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Figure 3.	Behavioral despair of depression-like behavior 
Depression-like behavior in the forced swim test in mice treated with sucrose, fluoxetine, 
or 8-OH-DPAT from P1-P21. (A) Floating time. (B) Swimming time. (C) Climbing time. 
Each bar represents the mean ± S.E.M (n=14 for control, n=13 for fluoxetine, n=13 for 
8-OH-DPAT). ** p < 0.01  
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Figure 4. Anhedonia of depression-like behavior 
Depression-like behavior in the sucrose preference test in mice treated with sucrose, 
fluoxetine, or 8-OH-DPAT from P1-P21. Each bar represents the mean ± S.E.M of 
sucrose preference (n=14 for control, n=13 for fluoxetine, n=14 for 8-OH-DPAT).  
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Figure 5. Spatial learning and memory in fluoxetine treated mice  
Spatial learning and memory in the Morris water maze in mice treated with sucrose or 
fluoxetine from P1-P21. (A) Training. (B) Probe test. (C) Cued test. Each bar represents 
the mean ± S.E.M. (n=9 for sucrose, n=6 for fluoxetine).  
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Figure 6. Spatial learning and memory in 8-OH-DPAT treated mice 
Spatial learning and memory in the Morris water maze in mice treated with saline or 8-
OH-DPAT from P1-P21. (A) Training. (B) Probe test. (C) Cued test. Each bar represents 
the mean ± S.E.M. (n=13 for saline, n=8 for 8-OH-DPAT).  
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Figure 7. Pain sensitivity 
Pain sensitivity in the hot plate test in mice treated with fluoxetine or 8-OH-DPAT from 
P1-P21. (A) The effects of fluoxetine. (n=10 for control, n=8 for fluoxetine) (B) The 
effects of  8-OH-DPAT (n=18 for control, n=13 for 8-OH-DPAT).  Each bar represents 
the mean ± S.E.M of latency. 
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Figure 8. The mRNA expression of the 5-HT1A receptor  
The mRNA expression of the 5-HT1A receptor in the mPFC, amygdala, dorsal 
hippocampus, and ventral hippocampus in mice treated with sucrose, fluoxetine, or 8-
OH-DPAT from P1-P21. (A) The mRNA expression of the 5-HT1A receptor at P22. (B) 
The mRNA expression of the 5-HT1A receptor at P71. Each bar represents the mean ± 
S.E.M of latency (n=6~10 for each group). * p < 0.05, ** p < 0.01 
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Figure 9. The mRNA expression of BDNF 
The mRNA expression of BDNF in the mPFC, amygdala, dorsal hippocampus, and 
ventral hippocampus in mice treated with sucrose, fluoxetine, or 8-OH-DPAT from P1-
P21. (A) The mRNA expression of BDNF at P22. (B) The mRNA expression of BDNF 
at P71. Each bar represents the mean ± S.E.M of latency (n=5~12 for each group). * p < 
0.05, ** p < 0.01, *** p < 0.001  
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Figure 10. The mRNA expression of the GABAA receptor  
The mRNA expression of the GABAA receptor α2 and α3 subunits at P71 in the mPFC, 
amygdala, dorsal hippocampus, and ventral hippocampus in mice treated with sucrose, 
fluoxetine, or 8-OH-DPAT from P1-P21. (A) The mRNA expression of the GABAA 
receptor α2 subunit. (B) The mRNA expression of the GABAA receptor α3 subunit.  
Each bar represents the mean ± S.E.M of latency (n=5~10 for each group). * p < 0.05,  
** p < 0.01, *** p < 0.001  
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Figure 11. The mRNA expression of the GluR   
The mRNA expression of the GluR1 and GluR2 at P71 in the mPFC, dorsal 
hippocampus, and ventral hippocampus in mice treated with sucrose, fluoxetine, or 8-
OH-DPAT from P1-P21. (A) The mRNA expression of the GluR1. (B) The mRNA 
expression of the GluR2.  Each bar represents the mean ± S.E.M of latency (n=6~9 for 
each group). * p < 0.05 
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Figure 12. Correlation between the 5-HT1A receptor and BDNF  
Correlation between the mRNA expression of the 5-HT1A receptor and BDNF in the 
mPFC at P71. (r = 0.664, p < 0.001) 
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Genes	 Primer sequences	 Tm (℃)	 Length (bp)	
5-HT1AR	 F: 5’-CCGTGAGAGGAAGACAGTGAAGAC-3’R: 5’-GGTTGAGCAGGGAGTTGGAGTAG-3’	
60.5
62.2	
176
	
BDNF	 F: 5’-GACAAGGCAACTTGGCCTAC-3’
R: 5’-ACTGTCACACACGCTCAGCTC-3’
58.4
60.4	
353	
GABAAR α2	 F: 5’-GAGAATCGGTGCCAGCAAGAA-3’R: 5’-CAGTCCATGGCAGTGGCATAA-3’	
64.9
64.2	
118	
GABAAR α3	 F: 5’-TTTCAGGCCCAGTCACTTTGTTC-3’R: 5’-TTCACACCTCATTACAACTGGCATC-3’	
64.7
64.4
80	
GluR1	 F: 5’-AGCGGACAACCACCATCTCTG-3’
R: 5’-AAGGGTCGATTCTGGGATGTTTC-3’	
64.8
64.6
80	
GluR2	 F: 5’-ATGGAACATTAGACTCTGGCTCCAC-3’
R: 5’-CTGCCGTAGTCCTCACAAACACA-3’	
63.9
64.6	
123	
18S rRNA	 F: 5’-ACTCAACACGGGAAACCTCA-3’
R: 5’-AACCAGACAAATCGCTCCAC-3’	
56.1
53.9	
123	
Table 1. Primer sequences for real-time reverse transcription-PCR	
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Age	 Control	 Fluoxetine	 8-OH-DPAT	 P value	
P1	 1.7 ± 0.0	 1.8 ± 0.0	 1.7 ± 0.0	 ns	
P7	 4.9 ± 0.1	 5.1 ± 0.1	 4.7 ± 0.1	 ns	
P14	 8.2 ± 0.1	 8.5 ± 0.2	 8.4 ± 0.1	 ns	
P21	 9.5 ± 0.2	 9.4 ± 0.2	 9.4 ± 0.1	 ns	
P71	 24.5 ± 0.5	 24.5 ± 0.3	 24.8 ± 0.4	 ns	
Unit of body weight is g. 
Data are shown as the mean ± S.E.M. ns; no significant effect 	
P1-P21; n=33 for control, n=34 for fluoxetine, n=34 for 8-OH-DPAT. P71; n=12 
for control, n=14 for fluoxetine, n=15 for 8-OH-DPAT.	
Table 2. Body weights of mice from P1 to P71 treated postnatally with 
fluoxetine and 8-OH-DPAT. 
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Fluoxetine	 8-OH-DPAT	
Anxiety	
Depression	
Behavioral despair	 ＝	
Anhedonia	 ＝	 ＝	
Spatial learning and memory	 ＝	 ＝	
Pain sensitivity	 ＝	 ＝	
↑, increase compared to control; ↓, decrease compared to control; ＝, no changes 
compared to control 
Table 3. Effects on behaviors in adulthood 
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↓, decrease compared to control; ＝, no changes compared to control 
mPFC, medial prefrontal cortex; Amyg, amygdala; dH, dorsal hippocampus; vH, 
ventral hippocampus	
Fluoxetine	 8-OH-DPAT	
5-HT1AR	
mPFC	
Amyg	 ＝	
dH	 ＝	
vH	
BDNF	
mPFC	
Amyg	 ＝	 ＝	
dH	 ＝	 ＝	
vH	 ＝	 ＝	
Table 4. Effects on the mRNA expressions at P22  
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Fluoxetine	 8-OH-DPAT	
5-HT1AR	
mPFC	 ＝	
Amyg	 ＝	 ＝	
dH	 ＝	 ＝	
vH	 ＝	 ＝	
BDNF	
mPFC	 ＝	
Amyg	 ＝	 ＝	
dH	 ＝	 ＝	
vH	 ＝	 ＝	
GABAAR 
α2	
mPFC	 ＝	
Amyg	 ＝	 ＝	
dH	 ＝	 ＝	
vH	 ＝	
GABAAR 
α3	
mPFC	
Amyg	 ＝	
dH	 ＝	 ＝	
vH	
GluR1	
mPFC	 ＝	 ＝	
Amyg	 ＝	 ＝	
dH	 ＝	 ＝	
GluR2	
vH	 ＝	 ＝	
mPFC	 ＝	 ＝	
Amyg	 ＝	 ＝	
↓, decrease compared to control; ＝, no changes compared to control 
mPFC, medial prefrontal cortex; Amyg, amygdala; dH, dorsal hippocampus; vH, ventral 
hippocampus	
Table 5. Effects on the mRNA expressions at P71	
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